VANCOUVER, BC , Dec. 4, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy program using our developed and in vitro validated Smart-siRNA sequences, which when paired with our proprietary bioresponsive lipid-nanoparticulate delivery systems (US... Read More

VANCOUVER, BC , Sept. 18, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is proud to announce that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this... Read More

VANCOUVER, BC , Sept. 12, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), PreveCeutical Medical Inc. marks today as an important chapter in the journey of PreveCeutical Medical Inc., a pioneering figure in the realm of medical technology. The Company unveils a comprehensive narrative around its growing involvement and innovation in the vast domain of... Read More

VANCOUVER, BC , Aug. 31, 2023 /CNW/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announces that it has entered into a Service Agreement dated effective September 1, 2023 (the " Agreement ") with New to the Street Group LLC (" NTTS "), whereby NTTS will provide production and broadcasting services (the " Services ") to the Company involving television, production,... Read More

VANCOUVER, BC , July 24, 2023 /CNW/ - PreveCeutica l Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress Cyclic peptides and uses thereof of its patent families. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of two of its patent families. The patent family based on PCT/AU2021/051383 (P114915, Sol-gel cannabinoid formulation and antiviral use), has now entered the national phase in Europe and... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 30, 2023) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to Sol-Gel (International Patent Application No. PCT/AU2021/051383, Sol-Gel Cannabinoid Formulation and Antiviral Use) and is taking the International patent... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that on April 21, 2023, PreveCeutical created a new division to develop and train an Artificial Intelligence (AI) tool that will be capable of learning R&D, clinical trials, and other clinical information. PreveCeutical plans to use this... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that Stephen Van Deventer will be participating in a live interactive video conference Q&A forum on April 25, 2023. All participants are encouraged to pre-register to ensure access to the live virtual event and to submit any questions... Read More

Synthesized Kappa Opioid Receptors (KOP) Appear to be Devoid of Many Problematic Mu Receptor Side-effects Such as Tolerance, Addiction, Sedation, and Euphoria/Dysphoria, KOP Peptides Showed Significant Opioid-like Antinociception Comparable to Morphine and U50844H PreveCeutical's Pain Management Peptides Program Published in the Swiss Medical Journal Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) -... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023 , to complete the following. Conduct a comprehensive gap analysis to both confirm current conclusions as... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of its Sol-Gel Cannabinoid Therapies patent family based on International Patent Application PCT/IB2021/022211 (Thermoresponsive Sol-Gels containing cannabinoids), and is taking the... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the appointment of Mr. Evan Ballantyne to the Company's board of directors (the "Board") effective February 17, 2023. Mr. Ballantyne has extensive executive leadership experience and has spent the last 20 years as a public and private company Chief... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following. Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 25, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce the grant of Australian patent no. 2018305726, titled "Disulfide bond containing compounds and uses thereof," on January 5, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to peptide analogues of dynorphin and their use in pain management (International Patent Application No. PCT/AU2021/050707, Peptides and Uses) and is taking the... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ( "Endosane") , a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 9, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the "Subsidiary" or "PAPL") for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce it has filed a PCT (Patent Cooperation Treaty) application number PCT/IB2022/06117 on November 18, 2022, entitled "Peptides and Uses Thereof", with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer. This patent application is... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces that it has entered into an assignment agreement with a certain arm's length assignee (the "Assignee"). Per the assignment agreement, the Assignee acquired all of Stephen Van Deventer and Kimberly Van Deventer's rights, title, interests and obligations in and under a convertible credit facility agreement dated... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces the appointment of Ms. Kathleen Rotika ("Kathy") to the Company's board of directors (the "Board"). Kathy is a CPA and Principal of Somerset CPA's P.C. She is a finance, operations, and strategy-focused executive with extensive experience with large medical groups. Her experience includes financial performance... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces the resignation of Mr. Sachin Nanavati as a member of the Company's board of director (the "Board") for personal reasons effective September 16, 2022. Stephen Van Deventer, PreveCeutical's Chief Executive Officer, commented, "We thank Mr. Nanavati for considering to be on the Company's Board and wish him all the... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces the appointment of Mr. Sachin Nanavati to the Company's board of directors (the "Board") effective September 1, 2022. Sachin is currently the Head of Industry, Healthcare with Google, Inc. He has vast knowledge and experience with healthcare and technology. Sachin was a founding member of Meta (Facebook)'s Health... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a $3 million credit facility agreement with the Company's Chief Executive Officer and Chair, Stephen Van Deventer, and the Company's former President and director, Kimberly Van Deventer (collectively, the "Lenders"). Effective July 18, 2022, the Company entered into a convertible credit... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces the resignation of Mr. Anderson and Mr. Lotz and the appointment of Dr. Linnéa Olofsson to the Company's board of directors (the "Board"). Resignation of Directors Mr. Keith Anderson and Mr. Mark Lotz will be stepping down as directors of the Company effective May 31, 2022, to allow them more time to focus on their... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that the British Journal of Pharmacology (the "BJP"), published an article on April 29, 2022, on the design and development of its non-addictive analgesic program ("Analgesic Program") under the running title, " Short dynorphin-like peptide agonists for kappa opioid receptors" click here to see the... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") announces that it has issued 11,600,000 common shares without par value in its capital (each, a " Share ") to two non-arm's length creditors and an arm's length creditor of the Company at a deemed issuance price of $0.025 per Share. The Company entered into shares for debt settlement agreements with a current director and... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce the settlement of the proposed class action filed by Michael Tietz and Duane Loewen against the Company and many other parties in B.C. Supreme Court Action No. S197731, Vancouver Registry (the "Action"). PreveCeutical commenced its own action against some of the defendants to the Action claiming... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce it has filed an international patent application on November 19, 2021, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use" (the "Invention"), claiming priority from Australian patent application number 2020904291. The patent is for an invention that relates to an antiviral... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce it has filed a provisional application at the Australian Patent Office on November 18, 2021, entitled "Peptides and Uses Thereof", application number 2021903722, with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer. Compounds... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company") , is pleased to announce that it has signed a license agreement with UniQuest Pty Ltd. ("UniQuest") giving PreveCeutical exclusive rights to UniQuest's Sol-Gel ("Sol-Gel License") technology for the delivery of cannabinoids. The licence agreement provides PreveCeutical with the right to use the technology to deliver... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is very pleased to announce the appointment of Dr. Caroline MacCallum as a senior advisor and consultant for the Company. Dr. MacCallum will be working with our team on the development and commercialization of the Company's Cannabinoid Sol-gel products. Her specialization in internal medicine and expertise in complex pain... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce that it has received a AU$315,338 cash rebate from the Australian Federal Government's Research and Development ("R&D") Incentive Program. The cash refund is related to expenditure on eligible Australian R&D activities conducted during the financial year ended December 31, 2020. The R&D activities were... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce it has filed an International PCT application on July 1, 2021, entitled "Peptides and uses thereof", application number PCT/AU2021/050707 with the aim of seeking protection for certain peptides and their use in pain management. There is a need for the development of new drugs that are effective in pain... Read More

PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is pleased to provide the following update. The Company's highest priority is to create shareholder value through the development and commercialization of products and delivery technology. The Company has partnered with UniQuest Pty Limited and the University of Queensland through its Australian subsidiary, PreveCeutical... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is pleased to announce the appointment of Aditya Bahl as an advisor and consultant for the Company. Mr. Bahl brings over 20 years of experience in pharmaceutical marketing and clinical development. He is the CEO and founder of RAS LSS, a boutique healthcare consulting group based in Germany. He provides strategic guidance to... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the " Company " or " PreveCeutical ") announces that it has agreed to issue 19,554,201 common shares without par value in its capital (each, a " Share ") to two non-arm's length creditors and an arm's length creditor of the Company at a deemed issuance price of $0.032 per Share. The Company entered into shares for debt settlement agreements with a current... Read More

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , is very pleased to announce the appointment of Dr. Linnéa Olofsson as an advisor and consultant for the Company. Dr. Olofsson will be working with our team in implementing our strategies for the commercialization of our products. With her scientific background and ability to understand the needs in the medical field, she... Read More

PreveCeutical Medical Inc (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce the successful completion of its non-addictive analgesic program ("Analgesic Program"). The Analgesic Program started in July 2018 to discover and develop peptide-based therapeutics for moderate to severe pain and inflammation. The Company has received the final research project report from UniQuest Pty... Read More